Laboratory Medicine ›› 2025, Vol. 40 ›› Issue (3): 271-277.DOI: 10.3969/j.issn.1673-8640.2025.03.012
Previous Articles Next Articles
ZHANG Haoyang, LU Lin, ZONG Ming, HE Long, DING Yuanyuan, FAN Lieying(
)
Received:2023-05-15
Revised:2024-04-16
Online:2025-03-30
Published:2025-04-10
CLC Number:
ZHANG Haoyang, LU Lin, ZONG Ming, HE Long, DING Yuanyuan, FAN Lieying. Diagnostic and predictive value of white blood cell population data in patients with sepsis[J]. Laboratory Medicine, 2025, 40(3): 271-277.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2025.03.012
| 组别 | 例数 | 性别 | 年龄/岁 | 白细胞计数/(×109·L-1) | 中性粒细胞百分比% | |
|---|---|---|---|---|---|---|
| 男/例 | 女/例 | |||||
| 脓毒血症组 | 44 | 31 | 13 | 75.00(66.00,84.00)* | 14.43(10.31,21.39)*# | 86.50(80.13,93.00)*# |
| 肺炎组 | 27 | 14 | 13 | 81.00(68.00,86.00)* | 7.68(5.67,9.40) | 71.35(61.60,81.88)* |
| 健康对照组 | 20 | 11 | 9 | 29.00(25.25,32.75) | 5.55(4.82,6.68) | 56.20(49.33,60.38) |
| 统计值 | 2.900 | 43.551 | 65.218 | 72.120 | ||
| P值 | 0.233 | <0.001 | <0.001 | <0.001 | ||
| 组别 | 单核细胞百分比/% | 血红蛋白/(g·L-1) | 血小板/(×109·L-1) | CRP/(mg·L-1) | ||
| 脓毒血症组 | 5.80(3.15,7.58)# | 107.56±29.29*# | 178.00(103.00,261.25)# | 90.09(32.05,189.17)# | ||
| 肺炎组 | 8.00(6.18,9.05) | 116.24±16.72* | 249.50(144.50,309.50) | 16.19(5.22,38.52) | ||
| 健康对照组 | 7.35(6.43,7.68) | 143.55±12.74# | 255.00(214.75,281.00) | |||
| 统计值 | 17.857 | 18.023 | 13.630 | -5.910 | ||
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | ||
| 组别 | 血清淀粉样蛋白A/(mg·L-1) | PCT/(ng·mL-1) | 白细胞介素-6/(pg·mL-1) | |||
| 脓毒血症组 | 225.86(79.26,288.00)# | 2.14(0.24,30.57)# | 115.40(28.00,766.15)# | |||
| 肺炎组 | 23.60(8.78,119.61) | 0.10(0.06,0.21) | 13.92(7.52,28.63) | |||
| 健康对照组 | ||||||
| 统计值 | -4.160 | -6.610 | -5.690 | |||
| P值 | <0.001 | <0.001 | <0.001 | |||
| 组别 | 例数 | 性别 | 年龄/岁 | 白细胞计数/(×109·L-1) | 中性粒细胞百分比% | |
|---|---|---|---|---|---|---|
| 男/例 | 女/例 | |||||
| 脓毒血症组 | 44 | 31 | 13 | 75.00(66.00,84.00)* | 14.43(10.31,21.39)*# | 86.50(80.13,93.00)*# |
| 肺炎组 | 27 | 14 | 13 | 81.00(68.00,86.00)* | 7.68(5.67,9.40) | 71.35(61.60,81.88)* |
| 健康对照组 | 20 | 11 | 9 | 29.00(25.25,32.75) | 5.55(4.82,6.68) | 56.20(49.33,60.38) |
| 统计值 | 2.900 | 43.551 | 65.218 | 72.120 | ||
| P值 | 0.233 | <0.001 | <0.001 | <0.001 | ||
| 组别 | 单核细胞百分比/% | 血红蛋白/(g·L-1) | 血小板/(×109·L-1) | CRP/(mg·L-1) | ||
| 脓毒血症组 | 5.80(3.15,7.58)# | 107.56±29.29*# | 178.00(103.00,261.25)# | 90.09(32.05,189.17)# | ||
| 肺炎组 | 8.00(6.18,9.05) | 116.24±16.72* | 249.50(144.50,309.50) | 16.19(5.22,38.52) | ||
| 健康对照组 | 7.35(6.43,7.68) | 143.55±12.74# | 255.00(214.75,281.00) | |||
| 统计值 | 17.857 | 18.023 | 13.630 | -5.910 | ||
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | ||
| 组别 | 血清淀粉样蛋白A/(mg·L-1) | PCT/(ng·mL-1) | 白细胞介素-6/(pg·mL-1) | |||
| 脓毒血症组 | 225.86(79.26,288.00)# | 2.14(0.24,30.57)# | 115.40(28.00,766.15)# | |||
| 肺炎组 | 23.60(8.78,119.61) | 0.10(0.06,0.21) | 13.92(7.52,28.63) | |||
| 健康对照组 | ||||||
| 统计值 | -4.160 | -6.610 | -5.690 | |||
| P值 | <0.001 | <0.001 | <0.001 | |||
| 组别 | NE-SFL | NE-WY | NE-WZ | MO-X | MO-WX | MO-WZ |
|---|---|---|---|---|---|---|
| 脓毒血症组 | 50.40 (46.65,55.20)*# | 717.5 (642.3,832.5)*# | 651.5 (614.0,713.5)* | 123.4 (120.9,125.7)*# | 267.5 (248.8,293.3)# | 577.0 (539.8,631.5)* |
| 肺炎组 | 46.45 (44.73,49.00) | 616.5 (589.8,634.5)* | 642.0 (604.0,701.0) | 120.8 (119.3,122.7) | 248.0 (235.0,271.3)* | 590.5 (551.5,656.8) |
| 健康对照组 | 43.60 (43.03,46.88) | 579.0 (558.5,595.8) | 615.5 (587.5,642.0) | 119.7 (118.6,121.0) | 276.0 (254.3,290.5) | 536.0 (511.0,583.5) |
| 统计值 | 39.632 | 70.366 | 8.978 | 33.800 | 12.705 | 7.928 |
| P值 | <0.001 | <0.001 | 0.011 | <0.001 | 0.002 | 0.019 |
| 组别 | NE-SFL | NE-WY | NE-WZ | MO-X | MO-WX | MO-WZ |
|---|---|---|---|---|---|---|
| 脓毒血症组 | 50.40 (46.65,55.20)*# | 717.5 (642.3,832.5)*# | 651.5 (614.0,713.5)* | 123.4 (120.9,125.7)*# | 267.5 (248.8,293.3)# | 577.0 (539.8,631.5)* |
| 肺炎组 | 46.45 (44.73,49.00) | 616.5 (589.8,634.5)* | 642.0 (604.0,701.0) | 120.8 (119.3,122.7) | 248.0 (235.0,271.3)* | 590.5 (551.5,656.8) |
| 健康对照组 | 43.60 (43.03,46.88) | 579.0 (558.5,595.8) | 615.5 (587.5,642.0) | 119.7 (118.6,121.0) | 276.0 (254.3,290.5) | 536.0 (511.0,583.5) |
| 统计值 | 39.632 | 70.366 | 8.978 | 33.800 | 12.705 | 7.928 |
| P值 | <0.001 | <0.001 | 0.011 | <0.001 | 0.002 | 0.019 |
| 项目 | AUC(95%可信区间) | P值 | 最佳临界值 | 敏感性/% | 特异性/% | 阳性预测值 | 阴性预测值 | 约登指数 |
|---|---|---|---|---|---|---|---|---|
| NE-SFL | 0.734(0.650~0.819) | <0.001 | 49.30 | 61.9 | 80.0 | 83.87 | 55.56 | 0.419 |
| NE-WY | 0.841(0.774~0.909) | <0.001 | 641.00 | 77.4 | 84.0 | 87.67 | 68.85 | 0.614 |
| MO-X | 0.727(0.641~0.813) | <0.001 | 124.05 | 44.0 | 92.0 | 90.24 | 49.46 | 0.360 |
| CRP | 0.817(0.743~0.891) | <0.001 | 55.54 | 87.8 | 69.4 | 89.29 | 66.15 | 0.572 |
| PCT | 0.862(0.799~0.925) | <0.001 | 0.29 | 88.6 | 71.4 | 85.00 | 65.57 | 0.601 |
| NE-SFL+NE-WY+MO-X | 0.884(0.825~0.943) | <0.001 | 0.509 | 81.0 | 86.0 | 79.79 | 77.50 | 0.67 |
| NE-WY+PCT | 0.924(0.875~0.972) | <0.001 | 0.590 | 80.5 | 95.5 | 87.06 | 91.43 | 0.76 |
| 项目 | AUC(95%可信区间) | P值 | 最佳临界值 | 敏感性/% | 特异性/% | 阳性预测值 | 阴性预测值 | 约登指数 |
|---|---|---|---|---|---|---|---|---|
| NE-SFL | 0.734(0.650~0.819) | <0.001 | 49.30 | 61.9 | 80.0 | 83.87 | 55.56 | 0.419 |
| NE-WY | 0.841(0.774~0.909) | <0.001 | 641.00 | 77.4 | 84.0 | 87.67 | 68.85 | 0.614 |
| MO-X | 0.727(0.641~0.813) | <0.001 | 124.05 | 44.0 | 92.0 | 90.24 | 49.46 | 0.360 |
| CRP | 0.817(0.743~0.891) | <0.001 | 55.54 | 87.8 | 69.4 | 89.29 | 66.15 | 0.572 |
| PCT | 0.862(0.799~0.925) | <0.001 | 0.29 | 88.6 | 71.4 | 85.00 | 65.57 | 0.601 |
| NE-SFL+NE-WY+MO-X | 0.884(0.825~0.943) | <0.001 | 0.509 | 81.0 | 86.0 | 79.79 | 77.50 | 0.67 |
| NE-WY+PCT | 0.924(0.875~0.972) | <0.001 | 0.590 | 80.5 | 95.5 | 87.06 | 91.43 | 0.76 |
| 项目 | 真阳性率/% | 假阴性率/% |
|---|---|---|
| NE-SFL | 71.83 | 28.17 |
| NE-WY | 91.55 | 8.45 |
| MO-X | 47.89 | 52.11 |
| CRP | 73.02 | 26.98 |
| PCT | 82.61 | 17.39 |
| NE-SFL+NE-WY+MO-X | 97.14 | 2.86 |
| NE-WY+PCT | 97.14 | 2.86 |
| 项目 | 真阳性率/% | 假阴性率/% |
|---|---|---|
| NE-SFL | 71.83 | 28.17 |
| NE-WY | 91.55 | 8.45 |
| MO-X | 47.89 | 52.11 |
| CRP | 73.02 | 26.98 |
| PCT | 82.61 | 17.39 |
| NE-SFL+NE-WY+MO-X | 97.14 | 2.86 |
| NE-WY+PCT | 97.14 | 2.86 |
| [1] | SINGER M, DEUTSCHMAN C S, SEYMOUR C W, et al. The third international consensus definitions for sepsis and septic shock(sepsis-3)[J]. JAMA, 2016, 315(8):801-810. |
| [2] | FLEISCHMANN C, SCHERAG A, ADHIKARI N K, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations[J]. Am J Respir Crit Care Med, 2016, 193(3):259-272. |
| [3] | GYAWALI B, RAMAKRISHNA K, DHAMOON A S. Sepsis:the evolution in definition,pathophysiology,and management[J]. SAGE Open Med, 2019, 7:2106907043. |
| [4] |
SHASHIKUMAR S P, STANLEY M D, SADIQ I, et al. Early sepsis detection in critical care patients using multiscale blood pressure and heart rate dynamics[J]. J Electrocardiol, 2017, 50(6):739-743.
DOI PMID |
| [5] |
MORTAZ E, ALIPOOR S D, ADCOCK I M, et al. Update on neutrophil function in severe inflammation[J]. Front Immunol, 2018, 9:2171.
DOI PMID |
| [6] |
LI Y, WANG W, YANG F, et al. The regulatory roles of neutrophils in adaptive immunity[J]. Cell Commun Signal, 2019, 17(1):147.
DOI PMID |
| [7] | MARTINS P S, KALLAS E G, NETO M C, et al. Upregulation of reactive oxygen species generation and phagocytosis,and increased apoptosis in human neutrophils during severe sepsis and septic shock[J]. Shock, 2003, 20(3):208-212. |
| [8] |
TAK T, VAN GROENENDAEL R, PICKKERS P, et al. Monocyte subsets are differentially lost from the circulation during acute inflammation induced by human experimental endotoxemia[J]. J Innate Immun, 2017, 9(5):464-474.
DOI PMID |
| [9] | YONA S, JUNG S. Monocytes:subsets,origins,fates and functions[J]. Curr Opin Hematol, 2010, 17(1):53-59. |
| [10] | XU D. Clinical applications of leukocyte morphological parameters[J]. Int J Pathol Clin Res, 2015, 1:1-4. |
| [11] | EVANS L, RHODES A, ALHAZZANI W, et al. Surviving sepsis campaign:international guidelines for management of sepsis and septic shock 2021[J]. Intensive Care Med, 2021, 47(11):1181-1247. |
| [12] | 曹钰, 柴艳芬, 邓颖, 等. 中国脓毒症/脓毒性休克急诊治疗指南(2018)[J]. 临床急诊杂志, 2018, 19(9):567-588. |
| [13] | LARSEN F F, PETERSEN J A. Novel biomarkers for sepsis:a narrative review[J]. Eur J Intern Med, 2017, 45:46-50. |
| [14] | KARON B S, TOLAN N V, WOCKENFUS A M, et al. Evaluation of lactate,white blood cell count,neutrophil count,procalcitonin and immature granulocyte count as biomarkers for sepsis in emergency department patients[J]. Clin Biochem, 2017, 50(16-17):956-958. |
| [15] | FAIX J D. Biomarkers of sepsis[J]. Crit Rev Clin Lab Sci, 2013, 50(1):23-36. |
| [16] | LIPPI G. Sepsis biomarkers:past,present and future[J]. Clin Chem Lab Med, 2019, 57(9):1281-1283. |
| [17] | HORECZKO T, GREEN J P, PANACEK E A. Epidemiology of the Systemic Inflammatory Response Syndrome(SIRS)in the emergency department[J]. West J Emerg Med, 2014, 15(3):329-336. |
| [18] |
NAUSEEF W M, BORREGAARD N. Neutrophils at work[J]. Nat Immunol, 2014, 15(7):602-611.
DOI PMID |
| [19] |
URRECHAGA E, BOVEDA O, AGUIRRE U. Role of leucocytes cell population data in the early detection of sepsis[J]. J Clin Pathol, 2018, 71(3):259-266.
DOI PMID |
| [20] | BUORO S, SEGHEZZI M, VAVASSORI M, et al. Clinical significance of cell population data(CPD)on Sysmex XN-9000 in septic patients with our without liver impairment[J]. Ann Transl Med, 2016, 4(21):418. |
| [21] | 朱美英, 曹鄂洪. 降钙素原的检测和应用——《感染相关生物标志物临床意义解读专家共识》解读[J]. 上海医药, 2018, 39(1):14-18. |
| [22] | PARK S H, PARK C J, LEE B R, et al. Sepsis affects most routine and cell population data(CPD)obtained using the Sysmex XN-2000 blood cell analyzer:neutrophil-related CPD NE-SFL and NE-WY provide useful information for detecting sepsis[J]. Int J Lab Hematol, 2015, 37(2):190-198. |
| [23] |
TANG H, JING J, BO D, et al. Biological variations of leukocyte numerical and morphologic parameters determined by UniCel DxH 800 hematology analyzer[J]. Arch Pathol Lab Med, 2012, 136(11):1392-1396.
DOI PMID |
| [24] | ARORA P, GUPTA P K, LINGAIAH R, et al. Volume,conductivity,and scatter parameters of leukocytes as early markers of sepsis and treatment response[J]. J Lab Physicians, 2019, 11(1):29-33. |
| [25] | PEREZ I, REDIN M E. Stability of leukocyte research parameters over time on the Sysmex XN:how to quantify the changes in cell morphology[J]. Int J Lab Hematol, 2018, 40(5):569-576. |
| [26] | SEGHEZZI M, BUORO S, PREVITALI G, et al. A preliminary proposal for quality control assessment and harmonization of leukocytes morphology-structural parameters(cell population data parameters)[J]. J Med Biochem, 2018, 37(4):486-498. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||